Quarterly 27 July 2021
Canine trial
Phrase 3 trial will proceed with the support of administering veterinarian
As reported in announcement 18 October 2021
Retrospective analysis of data of the phrase 2 trial shows the combination of mpl and prednisolone double the life expectancy of dogs compared to standard of care (prednisolone).
Quarterly issued 29 October 2021
Success in Phrase 2b trial in pet dogs with B cell lymphoma
Phrase 2 trial data shows the combination of mpl and prednisolone more than doubled the life expectancy of dogs over standard of care8
PAA is seeking partners to co develop and commercialise mpl for treatment veterinarian cancers.
PAA Post AGM ,, 2022 Highlights, page-101
-
- There are more pages in this discussion • 107 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
-0.010(4.88%) |
Mkt cap ! $77.20M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.8¢ | $342.8K | 1.779M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 52999 | 19.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 20.0¢ | 421000 | 3 |
View Market Depth
| Last trade - 16.10pm 27/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |